Vapreotide

Vapreotide is a synthetic octapeptide analog of somatostatin with preferential binding to somatostatin receptor subtypes 2 and 5 (SSTR2 and SSTR5). Developed as RC-160 by Andrew Schally's research group and later by Debiopharm, vapreotide was designed to combine the inhibitory properties of somatostatin with improved metabolic stability and pharmacokinetic properties suitable for clinical use.

Vapreotide has been primarily investigated and used for the acute management of bleeding esophageal varices, a life-threatening complication of portal hypertension most commonly seen in patients with liver cirrhosis. Like other somatostatin analogs, vapreotide reduces splanchnic blood flow and portal venous pressure by inhibiting the release of vasodilatory peptides, which helps control variceal hemorrhage. Clinical trials demonstrated that vapreotide, when combined with endoscopic therapy, improved bleeding control rates compared to endoscopic therapy alone.

The drug was approved in some countries (marketed as Sanvar) for the emergency treatment of acute variceal bleeding, though it has not received FDA approval in the United States. In clinical practice, octreotide is more commonly used for this indication due to its wider availability and more extensive clinical data.

Vapreotide has also been investigated for the treatment of neuroendocrine tumors, acromegaly, and other conditions where somatostatin receptor-mediated inhibition is beneficial. Research explored its potential antiproliferative effects on various tumor types expressing somatostatin receptors. However, its clinical development has been more limited than that of octreotide and lanreotide, and it remains a less widely used member of the somatostatin analog class.